1 / 87

New Antithrombotic Agents

New Antithrombotic Agents. Jason Taylor, MD PhD Oregon Health and Sciences University. Tom somewhere in Wyoming. DISCLOSURE. Relevant Financial Relationship(s) Speaker Bureau - None Consultant – Biogen Idec. What I am Talking About. New Antithrombotic Agents Dabigatran Rivaroxaban

brilliant
Télécharger la présentation

New Antithrombotic Agents

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. New Antithrombotic Agents Jason Taylor, MD PhD Oregon Health and Sciences University Tom somewhere in Wyoming

  2. DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant – Biogen Idec

  3. What I am Talking About • New Antithrombotic Agents • Dabigatran • Rivaroxaban • Apixaban • Compare and contrast trials • Practical issues in use

  4. New Anticoagulants A long time coming…

  5. New Anticoagulants • Warfarin and Heparin around since 1940’s • Now new drugs on market and late trials

  6. Disadvantages of Heparin • Not oral • Variable dosing (UFH) • Short half-life • Heparin thrombocytopenia • Injection site reactions

  7. Disadvantages of Warfarin • Drug interactions • Food interactions • Variable metabolism • Frequent monitoring

  8. Advantages of Old Anticoagulants • Familiarity • No unexpected side effects • Demonstrated use in multiple clinical areas

  9. New Anticoagulants • Two Classes • Thrombin inhibitors • Anti-Xa inhibitors

  10. Direct Thrombin Inhibitors • Thrombin is key step in thrombosis • Turns fibrinogen into clot • Activates platelets • Activates clotting factors

  11. Coagulation TF + VII IX + VIII X + V II CLOT

  12. DTI • Parental • Argatroban • Lepirudin • Bivalirudin • Oral • Ximelagatran • Dabigatran

  13. Factor Xa Inhibitors • Xa creates thrombin • Blocking prevents amplification of coagulation

  14. Coagulation TF + VII IX + VIII X + V II CLOT

  15. Factor Xa Inhibitors • Rivaroxaban • Apixaban • Endobaxiban • Betrixaban

  16. The Big Five

  17. Dabigatran • Oral Thrombin Inhibitor • Bioavailability: 6.5% • Onset of action: 2-3 hours • Half-life : 12-14 hours • Renal excretion: 80% • Drug interactions: p-glycoprotein • Rifampin

  18. Atrial Fibrillation • RCT of 18,113 • Warfarin INR 2-3 • Dabigatran 110mg or 150 mg BID • Mean F/u 2 years • N Engl J Med. 2009 Sep 17;361(12):1139-51.

  19. Atrial Fibrillation – 150mg • RCT • Warfarin INR 2-3 • Dabigatran 150 mg BID • More effective than warfarin • RR 0.66 (0.53-0.80) • No increase in bleeding • RR 0.93 (0.81-1.07) • Intracranial hemorrhage 0.40 (0.14-0.49)

  20. Atrial Fibrillation – 110mg • RCT • Warfarin INR 2-3 • Dabigatran 110 mg BID • Same as warfarin • RR 0.91 (0.74-1.11) • Decrease in bleeding • RR 0.80 (0.69-0.93) • Intracranial hemorrhage 0.32 (0.20-0.47)

  21. Effectiveness vs CHADS2

  22. DVT Therapy • NEJM Volume 361:2342-2352, 2009 • All patients got heparin • Randomized between warfarin and dabigatran 150 mg BID • N = 1274

  23. Recurrent DVT or Death

  24. Bleeding Dabigatran Major bleeding 0.82 (0.45 to 1.48; P=0.38) Dabigatran Any bleeding 0.71 (0.59 to 0.85; P<0.001)

  25. Side Effects • No difference in liver function tests • Increase in dyspepsia • 3.0 vs 0.7%

  26. Dabigatran • Effective in DVT prevention • 220mg dose in EU/Canada • Effective in DVT therapy • Effective in stroke prevention in atrial fibrillation • Same or lesser bleeding risk

  27. Dabigatran • Completed studies • DVT prophylaxis • DVT Therapy • Afib stroke prophylaxis • Ongoing • Long term DVT treatment • Cardiac Valves

  28. Dabigatran • 150 and 75 mg dose approved by FDA • Dosing • CrCl > 30 mL/ml– 150mg BID • CrCl 15-30mL/ml 75 mg BID • CrCl < 15 not indicated • No major drug-drug interactions • Rifampin

  29. Dabigatran- Surgery

  30. Monitoring • aPTT • 150 mg twice daily the median peak aPTT is approximately 2x control. • Twelve hours after the last dose the median aPTT is 1.5x control • Unsure if can be use to adjust dose • Assess compliance and drug effect • Reference labs can do specific level •  INR insensitive

  31. Rivaroxaban • Oral Xa Inhibitor • Bioavailability: 80-100% • Onset of action: 2.5-4 hours • Half-life : 5-9 hours • Renal excretion: ~66% • Drug interactions: CYP 3A4

  32. Total Hip Replacement R1: N Engl J Med. 2008 358:2765-75. R2: Lancet. 2008 372:31-9. * P < 0.01

  33. Total Knee Replacement * P < 0.01 R3: N Engl J Med. 2008 358:2776-86 R4: Lancet. 2009 373(9676):1673-80.

  34. Rivaroxaban in “Real World” • Beyer- Westendorf#210 • Retropective study of 5346 patients undergoing orthopedic surgery in 3 “eras” • LMWH • Fondaparnux • Rivoaroxaban

  35. Rivaroxaban in “Real World” • Rivaroxaban with • Less total VTE than LMWH or fondaparinux (distal) • Less bleeding • Major: L:14.9% F: 11.1% R:7.4% • Txn: L:14% F:11% R:7%

  36. Rivaroxaban in “Real World” • Restrospective • Suggests benefits of rivaroxaban may be better with clincal use

  37. Atrial Fibrillation • RCT of 14,264 • Warfarin INR 2-3 • Rivaroxaban 20mg • 15mg CrCl 49-30 • Mean F/u 1.6 years • N Engl J Med 2011; 365:883-891

  38. Atrial Fibrillation • RCT • Warfarin INR 2-3 • Rivaroxaban 20mg • As effective than warfarin • RR 0.79 (0.66-0.96) • No increase in bleeding • RR 1.04 (0.90-1.20) • Intracranial hemorrhage 0.67 (0.47-0.94)

  39. Atrial Fibrillation

  40. Rivaroxaban: Acute DVT Therapy • N = 3,449 with DVT • RCT • Rivaroxaban 15mg BID then 20mg Daily after 3 weeks • Enoxaparin -> Warfarin

  41. Results

  42. Acute DVTs

  43. Safety

  44. Extension Study • N = 1,197 • Finished 6-12 months of therapy • RCT: 20mg of rivaroxaban vs placebo • No increase in major bleeding

  45. Results

  46. DVT Recurrence DVT Recurrence

  47. Rivaroxaban • Effective in: • Prophylaxis • Atrial Fibrillation • DVT therapy • Acute Coronary syndromes • Ongoing • PE therapy

More Related